Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulmatrix Inc PULM

Healthcare Biotechnology
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious... see more

Recent & Breaking News (NDAQ:PULM)

Nasdaq Companies to Present Online to Investors on August 6

Canada NewsWire August 4, 2015

Pulmatrix to Webcast Investor Presentation and Provide Update on Pipeline of Inhaled Therapeutics August 6th

Canada NewsWire July 29, 2015

Pulmatrix to Webcast Investor Presentation and Provide Update on Pipeline of Inhaled Therapeutics August 6th

Canada NewsWire July 29, 2015

Pulmatrix Issued Patents Covering iSPERSE(TM) Technology for Treatment of Patients with Inhaled Dry Powders

PR Newswire July 23, 2015

Pulmatrix Appoints William Duke, Jr., as Chief Financial Officer

PR Newswire June 25, 2015

Pulmatrix Announces Appointment of Michael Higgins to Board of Directors

PR Newswire June 18, 2015